These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 16637790

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2003 Feb 19; 289(7):853-63. PubMed ID: 12588269
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
    Exaire JE, Butman SM, Ebrahimi R, Kleiman NS, Harrington RA, Schweiger MJ, Bittl JA, Wolski K, Topol EJ, Lincoff AM, REPLACE-2 Investigators.
    Am Heart J; 2006 Jul 19; 152(1):157-63. PubMed ID: 16824849
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Economic implications of bivalirudin in the cardiac catheterization laboratory.
    Bakhai A, Cohen DJ.
    Rev Cardiovasc Med; 2006 Jul 19; 7 Suppl 3():S35-42. PubMed ID: 17224883
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN, Wong SC, Gade CL, Gidseg DS, Bergman G, Minutello RM.
    Am Heart J; 2007 Oct 19; 154(4):695-701. PubMed ID: 17892994
    [Abstract] [Full Text] [Related]

  • 18. Direct thrombin inhibitors.
    Chen MS, Lincoff AM.
    Curr Cardiol Rep; 2005 Jul 19; 7(4):255-9. PubMed ID: 15987622
    [Abstract] [Full Text] [Related]

  • 19. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
    Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Feit F, Topol EJ, REPLACE-2 Investigators.
    Am J Cardiol; 2005 Mar 01; 95(5):581-5. PubMed ID: 15721095
    [Abstract] [Full Text] [Related]

  • 20. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ, ACUITY Investigators.
    JAMA; 2007 Dec 05; 298(21):2497-506. PubMed ID: 18056903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.